CIK 0001515673
- Large accelerated filer
Ultragenyx Pharmaceutical Inc.
Sign in to watch- Ticker
- RARE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 272546083
- Phone
- +1 415-483-8800
- Business address
- 60 LEVERONI COURT, NOVATO, CA, 94949
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $127,561
- in 3 filings, $17K under 10b5-1 plans
Net −$127,561. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-01 | Huang Dennis Karl See Remarks | Grant or award | +22,000 | 75,703 | ||
| 2023-03-01 | Huang Dennis Karl See Remarks | Sale | −389 | $45.65 | $18K | 75,314 |
| 2023-03-01 | Huang Dennis Karl See Remarks | Returned to the company | −10,599 | $45.65 | $484K | 64,715 |
| 2023-03-01 | Huang Dennis Karl See Remarks | Grant or award · Stock Option (Right to Buy) | +39,400 | 39,400 | ||
| 2023-03-01 | Pinion John Richard See Remarks | Grant or award | +2,663 | 61,929 | ||
| 2023-03-01 | Pinion John Richard See Remarks | Grant or award | +22,000 | 83,929 | ||
| 2023-03-01 | Pinion John Richard See Remarks | Sale | −3,755 | $45.26 | $170K | 80,174 |
| 2023-03-01 | Pinion John Richard See Remarks | Returned to the company | −4,014 | $45.65 | $183K | 76,160 |
| 2023-03-01 | Pinion John Richard See Remarks | Grant or award · 3/1/2023 | +39,400 | 39,400 | ||
| 2023-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +8,716 | 569,406 | ||
| 2023-03-01 | KAKKIS EMIL D President & CEO | Grant or award | +46,200 | 615,606 | ||
| 2023-03-01 | KAKKIS EMIL D President & CEO | Shares withheld for taxes | −16,140 | $45.65 | $737K | 599,176 |
| 2023-03-01 | KAKKIS EMIL D President & CEO | Grant or award · Stock Option (Right to Buy) | +83,500 | 83,500 | ||
| 2023-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +2,663 | 38,823 | ||
| 2023-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award | +22,000 | 60,823 | ||
| 2023-03-01 | Harris Erik EVP & Chief Commercial Officer | Sale | −3,664 | $45.25 | $166K | 57,344 |
| 2023-03-01 | Harris Erik EVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +39,400 | 39,400 | ||
| 2023-02-28 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −639 | $43.40 | $28K | 15,558 |
| 2022-12-30 | KAKKIS EMIL D President & CEO | Sale | −19,582 | $45.57 | $892K | 541,108 |
| 2022-12-21 | Huizenga Theodore Alan SVP, Chief Accounting Officer | Sale | −2,031 | $43.96 | $89K | 16,197 |
Page 14 of 21 · 410 trades